References
- Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008;7(12):1139–1151.
- Ruano L, Portaccio E, Goretti B, et al. Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. Mult Scler. 2017;23(9):1258–1267.
- Planche V, Gibelin M, Cregut D, et al. Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing–remitting, secondary progressive and primary progressive multiple sclerosis. Eur J Neurol. 2016;23(2):282–289.
- Clemens L, Langdon D. How does cognition relate to employment in multiple sclerosis? A systematic review. Mult Scler Relat Disord. 2018;26:183–191.
- Benedict RH, Cree B, Tomic D, et al. Impact of siponimod on cognition in patients with secondary progressive multiple sclerosis: results from phase 3 EXPAND study (S44.004). Neurology. 2018;90:S44.004.
- Riepl E, Pfeuffer S, Ruck T, et al. Alemtuzumab improves cognitive processing speed in active multiple sclerosis – a longitudinal observational study. Front Neurol. 2017;8:730.
- Maruszczak MJ, Montgomery SM, Griffiths MJ, et al. Cost–utility of fingolimod compared with dimethyl fumarate in highly active relapsing–remitting multiple sclerosis (RRMS) in England. J Med Econ. 2015;18(11):874–885.
- Allen F, Montgomery S, Maruszczak M, et al. Convergence yet continued complexity: a systematic review and critique of health economic models of relapsing–remitting multiple sclerosis in the United Kingdom. Value Health. 2015;18(6):925–938.
- Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–1452.
- The Lancet Neurology. Patient-reported outcomes in the spotlight. Lancet Neurol. 2019;18:981.
- Meyer-Moock S, Feng YS, Maeurer M, et al. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol. 2014;14(1):58.
- Vadapalle S, Vudumula U, Gudala K, et al. Factors influencing health-related quality of life in patients with secondary progressive multiple sclerosis using EXPAND trial data (PND97). Presented at: 22nd ISPOR Europe conference; 2018 Nov 2–6; Copenhagen, Denmark.
- EuroQol. EQ-5D instruments [cited Oct 2019]. Available from: https://euroqol.org/eq-5d-instruments/
- EuroQol. Valuation of EQ-5D [cited Oct 2019]. Available from: https://euroqol.org/eq-5d-instruments/valuation-of-eq-5d/
- Davis JC, Bryan S, McLeod R, et al. Exploration of the association between quality of life, assessed by the EQ-5D and ICECAP-O, and falls risk, cognitive function and daily function, in older adults with mobility impairments. BMC Geriatr. 2012;12(1):65.
- Eboni ACB, Cardoso M, Dias FM, et al. High levels of alexithymia in patients with multiple sclerosis. Dement Neuropsychol. 2018;12(2):212–215.
- Frank L, Lloyd A, Flynn JA, et al. Impact of cognitive impairment on mild dementia patients and mild cognitive impairment patients and their informants. Int Psychogeriatr. 2006;18(1):151–162.
- Easton T, Milte R, Crotty M, et al. An empirical comparison of the measurement properties of the EQ-5D-5L, DEMQOL-U and DEMQOL-Proxy-U for older people in residential care. Qual Life Res. 2018;27(5):1283–1294.
- Hounsome N, Orrell M, Edwards RT. EQ-5D as a quality of life measure in people with dementia and their carers: evidence and key issues. Value Health. 2011;14(2):390–399.
- Benedict RH, DeLuca J, Phillips G, et al. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler. 2017;23(5):721–733.
- Kappos L, Vermersch P, Cree BAC, et al. A novel functional composite endpoint to characterize disease progression in patients with secondary progressive multiple sclerosis. Presented at 71st AAN Annual Meeting; 2019 May 4–10; Philadelphia, USA.
- Krabbe PF, Stouthard ME, Essink-Bot ML, et al. The effect of adding a cognitive dimension to the EuroQol multiattribute health-status classification system. J Clin Epidemiol. 1999;52(4):293–301.
- Geraerds A, Bonsel GJ, Janssen MF, et al. The added value of the EQ-5D with a cognition dimension in injury patients with and without traumatic brain injury. Qual Life Res. 2019;28(7):1931–1939.